Young Patricia A, Migliorini Mary, Strickland Dudley K
From the Center for Vascular and Inflammatory Disease and the Departments of Surgery and Physiology, University of Maryland School of Medicine, Baltimore, Maryland 21201.
From the Center for Vascular and Inflammatory Disease and the Departments of Surgery and Physiology, University of Maryland School of Medicine, Baltimore, Maryland 21201
J Biol Chem. 2016 Dec 9;291(50):26035-26044. doi: 10.1074/jbc.M116.754622. Epub 2016 Oct 29.
Hemophilia A is a bleeding disorder caused by a deficiency in coagulation factor VIII (fVIII) that affects 1 in 5,000 males. Current prophylactic replacement therapy, although effective, is difficult to maintain due to the cost and frequency of injections. Hepatic clearance of fVIII is mediated by the LDL receptor-related protein 1 (LRP1), a member of the LDL receptor family. Although it is well established that fVIII binds LRP1, the molecular details of this interaction are unclear as most of the studies have been performed using fragments of fVIII and LRP1. In the current investigation, we examine the binding of intact fVIII to full-length LRP1 to gain insight into the molecular interaction. Chemical modification studies confirm the requirement for lysine residues in the interaction of fVIII with LRP1. Examination of the ionic strength dependence of the interaction of fVIII with LRP1 resulted in a Debye-Hückel plot with a slope of 1.8 ± 0.5, suggesting the involvement of two critical charged residues in the interaction of fVIII with LRP1. Kinetic studies utilizing surface plasmon resonance techniques reveal that the high affinity of fVIII for LRP1 results from avidity effects mediated by the interactions of two sites in fVIII with complementary sites on LRP1 to form a bivalent fVIII·LRP1 complex. Furthermore, although fVIII bound avidly to soluble forms of clusters II and IV from LRP1, only soluble cluster IV competed with the binding of fVIII to full-length LRP1, revealing that cluster IV represents the major fVIII binding site in LRP1.
甲型血友病是一种由凝血因子VIII(fVIII)缺乏引起的出血性疾病,每5000名男性中就有1人受其影响。目前的预防性替代疗法虽然有效,但由于注射成本和频率,难以维持。fVIII的肝脏清除是由低密度脂蛋白受体相关蛋白1(LRP1)介导的,LRP1是低密度脂蛋白受体家族的一员。虽然已经明确fVIII与LRP1结合,但这种相互作用的分子细节尚不清楚,因为大多数研究是使用fVIII和LRP1的片段进行的。在当前的研究中,我们研究了完整的fVIII与全长LRP1的结合,以深入了解分子相互作用。化学修饰研究证实了fVIII与LRP1相互作用中赖氨酸残基的必要性。对fVIII与LRP1相互作用的离子强度依赖性的研究产生了一个德拜-休克尔图,斜率为1.8±0.5,表明fVIII与LRP1相互作用中有两个关键的带电残基参与。利用表面等离子体共振技术的动力学研究表明,fVIII对LRP1的高亲和力源于fVIII中两个位点与LRP1上互补位点相互作用介导的亲和力效应,形成二价fVIII·LRP1复合物。此外,虽然fVIII与LRP1的可溶性簇II和IV形式紧密结合,但只有可溶性簇IV与fVIII与全长LRP1的结合竞争,这表明簇IV代表了LRP1中主要的fVIII结合位点。